Design of a Tumor Homing Cell-Penetrating Peptide for Drug Delivery

Adair CG, McElnay JC (1986) Studies on the mechanism of gastrointestinal absorption of melphalan and chlorambucil. Cancer Chemother Pharmacol 17(1):95–98

Arap W, Pasqualini R, Ruoslahti E (1998) Chemotherapy targeted to tumor vasculature. Curr Opin Oncol 10(6):560–565

Derossi D, Joliot AH, Chassaing G, Prochiantz A (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269(14):10444–10450

Elmquist A, Lindgren M, Bartfai T, Langel Ü (2001) VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. Exp Cell Res 269(2):237–244

Elmquist A, Hansen M, Langel Ü (2006) Structure-activity relationship study of the cell-penetrating peptide pVEC. Biochim Biophys Acta 1758(6):721–729

Essler M, Ruoslahti E (2002) Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci USA 99(4):2252–2257

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70

Holm T, Johansson H, Lundberg P, Pooga M, Lindgren M, Langel Ü (2006) Studying the uptake of cell-penetrating peptides. Nat Protoc 1(2):1001–1005

Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K (1996) A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 19(11):1518–1520

Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205(2):275–292

Mäe M, Langel Ü (2006) Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr Opin Pharmacol 6(5):509–514

Mazel M, Clair P, Rousselle C, Vidal P, Scherrmann JM, Mathieu D, Temsamani J (2001) Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs 12(2):107–116

Myrberg H, Zhang L, Mäe M, Langel Ü (2007) Design of a tumor-homing cell-penetrating peptide. Bioconjug Chem

Myrberg H, Zhang L, Mäe M, Langel Ü (2008) Design of a tumor-homing cell-penetrating peptide. Bioconjug Chem 19(1):70–75

O′Driscoll L, Clynes M (2006) Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets 6(5):365–384

Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, Testa JE, Schnitzer JE (2004) Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429(6992):629–635

Panasci L, Paiement JP, Christodoulopoulos G, Belenkov A, Malapetsa A, Aloyz R (2001) Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin Cancer Res 7(3):454–461

Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, Gabrilovich DI, Colombo G, Altieri DC (2005) Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7(5):457–468

Portlock CS, Fischer DS, Cadman E, Lundberg WB, Levy A, Bobrow S, Bertino JR, Farber L (1987) High-dose pulse chlorambucil in advanced, low-grade non-Hodgkin’s lymphoma. Cancer Treat Rep 71(11):1029–1031

Rousselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J (2000) New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 57(4):679–686

Ruoslahti E (2000) Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 10(6):435–442

Ruoslahti E (2002) Specialization of tumour vasculature. Nat Rev Cancer 2(2):83–90

Ruoslahti E, Duza T, Zhang L (2005) Vascular homing peptides with cell-penetrating properties. Curr Pharm Des 11(28):3655–3660

Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A (2004) Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res 64(19):7150–7155

Sacchi A, Gasparri A, Gallo-Stampino C, Toma S, Curnis F, Corti A (2006) Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin Cancer Res 12(1):175–182

Simberg D, Duza T, Park JH, Essler M, Pilch J, Zhang L, Derfus AM, Yang M, Hoffman RM, Bhatia S, Sailor MJ, Ruoslahti E (2007) Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci USA 104(3):932–936

Tan M, Lan KH, Yao J, Lu CH, Sun M, Neal CL, Lu J, Yu D (2006) Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res 66(7):3764–3772